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Despite a very active research in the field of nanomedicine, only a few nano-based drug delivery 
systems have reached the market. The “death valley” between research and commercialization has 
been partially attributed to the limited characterization and reproducibility of the nanoformulations. 
Our group has previously reported the potential of a peptide-based nanovaccine candidate for the 
prevention of SIV infection in macaques. This vaccine candidate is composed of chitosan/dextran 
sulfate nanoparticles containing twelve SIV peptide antigens. The aim of this work was to rigorously 
characterize one of these nanoformulations containing a specific peptide, following a quality-by-design 
approach. The evaluation of the different quality attributes was performed by several complementary 
techniques, such as dynamic light scattering, nanoparticle tracking analysis and electron microscopy 
for particle size characterization. The inter-batch reproducibility was validated by three independent 
laboratories. Finally, the long-term stability and scalability of the manufacturing technique were 
assessed. Overall, these data, together with the in vivo efficacy results obtained in macaques, 
underline the promise this new vaccine holds with regard to its translation to clinical trials.  
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In the last decades, nanotechnology has shown a great potential for the delivery of complex 
biomolecules [1–8] and particularly antigens [9–12]. Advances in this field have led to the clinical 
approval of a few tens of nanoformulations [13–15], and to the evaluation of many more in clinical 
trials [11,14]. Regardless of the type of formulation, nanomedicines are usually complex systems, 
where small changes in their production or composition can result in a decreased efficacy and, often, 
undesired side effects [16]. This complexity is also one of the main reasons that has hindered the 
commercialization of nanotechnology-based drugs [17,18]. For example, Couvreur  et al. have recently 
reported the challenges faced during the scale-up of squalene-adenosine NPs and the important 
differences in the physicochemical properties of lab- and industrial-scale batches [19]. Therefore, a 
detailed analytical characterization of the nanomedicines is a critical step to identify their most 
important manufacturing features, and to ensure their reproducibility, therapeutic efficacy and safety 
[16,20].  
Pharmaceutical quality-by-design (QbD) is a systematic approach that begins by predefining the 
characteristics of the targeted formulation. It is based on implementing statistical, analytical and risk-
management methods in order to understand the product and the processes involved in its fabrication 
[21]. The application of QbD is essential to guarantee the safety and efficacy of a formulation [21–24]. 
In addition, the knowledge generated through these approaches represents critical information to be 
considered by the regulatory authorities. The increasing application of QbD approaches for the 
development of nanoformulations will certainly contribute to generate more robust formulations [25–
30]. Additionally, as indicated by the MIRIBEL recommendations [31], the report of a minimum 
information about nano-delivery systems in terms of material and biological characterization, together 
with the experimental protocol details, will be another key aspect in the generation of more robust 
nanomedicines. 
Despite the important advances achieved in vaccination through the use of nanotechnology, still many 
infectious diseases (i.e., HIV, malaria or tuberculosis) remain elusive to vaccination [11]. Our group has 
dedicated significant efforts to the development of effective nanovaccines for different infectious 
diseases [32–35]. All this knowledge brought us to develop, in collaboration with investigators of the 
University of Manitoba, a potential HIV vaccine candidate based on polysaccharide nanoparticles (NPs) 
[36–38]. The vaccine is composed of twelve different small peptide antigens that target the protease 
cleavage sites (PCS) of the virus, that are associated to chitosan/dextran sulfate (CS/DS) NPs [36,38]. 
The promising results reported in macaques encouraged us to optimize and adapt the 
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nanoformulation for its production in a pilot plant for preclinical and, potentially, future clinical trials 
[36]. Considering that the formulation process for each of the peptides is the same, the technology 
transfer process was validated for the NPs containing only one peptide antigen (PCS5). For this 
purpose, and within the frame of the European Horizon 2020 project NANOPILOT, several research 
groups were involved in the development of the methods, techniques and a pilot plant to produce the 
nanovaccine. This work compiles part of the results generated within this consortium. Thus, in the 
following sections, we report the adaptation of the manufacturing procedure of an HIV nanovaccine 
candidate for its production in a pilot plant. The use of the QbD methodology involved the 
identification of the target product profile of the selected prototype, its critical quality attributes, and 
a risk analysis based on an Ishikawa diagram. Then, the influence of the manufacturing parameters on 
the final properties of the nanoformulation was assessed. A thorough characterization using 
orthogonal techniques was carried out in order to define the attributes of the nanoformulation. Finally, 
different scaling-up methodologies and an interlaboratory manufacturing transfer were conducted to 
study the translational potential of these polymeric NPs to an industrial environment. 
 
2. Materials and Methods 
2.1. Materials 
Chitosan (CS) (hydrochloride salt, molecular weight (MW) 42.7 KDa and 88% deacetylation degree) 
was obtained from HMC+ (Halle, Germany). Dextran sulfate (DS), (sodium salt, MW 8 KDa) was 
purchased from Dextran Products Ltd (ON, Canada). High purity α,α–trehalose dihydrate was 
purchased from Pfanstiehl (IL, USA). HIV PCS5 peptide (sequence GPWGKKPRNFPMAQVHQGLM, MW 
2280 Da and > 95% purity) was obtained from GenScript (NJ, USA).  
 
2.2. Quality-by-design (QbD) 
The quality target product profile (QTTP) and critical quality attributes (CQAs) of the nanoformulation 
were established based on previous knowledge, and recommendations from the International 
Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for 
Human Use (ICH), European Medicines Agency (EMA) and US Food and Drug Administration (FDA) 
[39,40]; and are summarized in Table 1 and Table 2. For the risk analysis, experts in different fields 
agreed on the design of an Ishikawa diagram and identified the most critical parameters that could 
have an effect on the nanoformulation CQAs (Fig. 1) [40].  
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2.3.  Nanoparticle preparation 
CS/DS NPs were prepared as previously described [36,37]. Briefly, 0.770 mL of a CS aqueous solution 
(0.67 mg/mL) were added to a test tube under mild magnetic stirring. A volume of 0.055 mL of PCS5 
in aqueous solution (4 mg/mL) was then added with a pipette. After 5 min of stirring, 0.825 mL of a DS 
aqueous solution (1.875 mg/mL) were added. The solution was stirred for 5 additional min, and the 
formulation was left standing for 10 min prior to characterization. For the preparation of blank NPs, 
the solution of PCS5 was replaced by ultrapure water.  
 
2.4. Nanoparticle freeze-drying 
A volume of 180 µL of trehalose 45% (wt) was added to 900 µL of NPs, mixed by horizontal shaking for 
at least 20 min, frozen at -80 ℃ for 2 h, and then freeze-dried (Genesis™ 25 EL, S.P Industries, PA, USA).  
Samples were first left in the freeze-drier at -40 ℃ for 4 h to guarantee that they were completely 
frozen, with a vacuum of 200 mTorr. Then, the first drying phase was done at a temperature ranging 
from -40 ℃ to +20 ℃, applying a progressive vacuum to 20 mTorr for a period of 43 h. Finally, the 
secondary drying phase was done for 3 h at +22 ℃ and 20 mTorr. At pre-determined times, the final 
cake was reconstituted in ultrapure water and NPs were conveniently characterized. 
 
2.5. Nanoparticle characterization 
2.5.1. Dynamic Light Scattering (DLS) 
The mean particle size (Z-average) and polydispersity index (PDI) of the non-diluted samples were 
characterized by DLS, following ISO standards [41]. The zeta potential values were determined by Laser 
Doppler Anemometry (LDA), measuring the mean electrophoretic mobility after a 10-times dilution of 
the NPs in ultrapure water. Derived count rate represents the scattering intensity measured in the 
absence of a laser light attenuation filter, and it was calculated as the ratio between the measured 
count rate and the attenuation factor. At USC and CIDETEC, these properties were measured using a 
Zetasizer® NanoZS, using the software Zetasizer v7.13 (Malvern Panalytical Ltd., Malvern, UK), at 25 ℃ 
and a detection angle of 173. At UT2A, DLS measurements were done in a VASCO-2 particle size 
analyzer (Cordouan Technology, France) in combination with the software nanoQ v 6.2.2, at 25 ℃ and 
a detection angle of 135. 
 
2.5.2.  Electron microscopy 
Field Emission Scanning Electron Microscopy (FESEM) (Zeiss Gemini Ultra Plus, Oberkochen, Germany) 
was used for morphology evaluation. Reconstituted freeze-dried NPs were diluted 1:100 in water, and 
	 7	
then diluted 1:1 with phosphotungstic acid (2% in water). 1 µL of sample was placed on a copper grid 
with carbon films and, once dried, washed with 1 mL of ultrapure water. When dried, samples were 
analyzed under the microscope using a STEM detector. ImageJ software was used for NP counting and 
analysis (n ≈ 100), by employing the Analyze/Analyze Particles command, in accordance to an already 
described method [42]. 
 
2.5.3. Nanoparticle tracking analysis (NTA) 
Reconstituted freeze-dried NPs were diluted 1:1000 in ultrapure water prior to analysis in a Nanosight 
NS300 (Malvern Panalytical Ltd., Malvern, UK) using the Nanosight NTA software v3.3. The camera 
gain was set at 11 or 13. Each sample was measured 5 times for 60 s each. 
 
2.5.4.  pH, osmolality, % of transmittance and moisture 
A freshly calibrated Sartorius Docu-pH Benchtop Meters (Thermo Fisher Scientific, MA, USA) was 
employed for the determination of the pH of the formulation at USC. A GLP2 pH-meter (Crison 
Scharlab, Barcelona, Spain) was used in CIDETEC for the determination of the pH of the final product. 
Osmolality was measured in a Gonotec Osmomat 030 Cryoscopic Osmometer (Gonotec GmbH, Berlin, 
Germany) at USC, or in a vapor pressure osmometer model 5600 Vapor (Wescor Vapro, Utah, USA) at 
CIDETEC. The values of percentage of transmittance were obtained either from a DU®730 UV/Vis 
Spectrophotometer (Beckman-Coulter, CS, USA) at USC, or from a UV-Visible spectrophotometer 
Shimazdu UV-2401PC (Shimazdu, Kyoto, Japan) at CIDETEC, both at a wavelength of 236 nm. The water 
content was determined by Karl-Fischer titration (Metrohm 899, Herisau, Switzerland). 
 
2.6. Filtration 
Millex®-GV filters (Millipore Corporation, MA, USA), of 13- or 33-mm diameter and 0.22 µm pore size 
of polyvinylidene fluoride (PVDF), polyethylene sulfone (PES) or polytetrafluoroethylene (PTFE) were 
used to filter NPs or polymer solutions. A volume of 0.5 mL of nanoformulation or 20 mL of polymer 







2.7. Peptide PCS5 quantification 
2.7.1. Particle disassembling 
For the particle disruption process, NPs were diluted in a 1:1 (v/v) ratio with the solution of KCl, and 
the derived count rate determined by DLS. As a control, NPs were diluted in the same proportion with 
water.  
 
2.7.2. UPLC analysis 
At USC, samples were analyzed by Ultra Performance Liquid Chromatography (UPLC) on an Acquity H-
UPLC Class system with a UV detector at 280 nm (Waters Corporation, MA, USA) equipped with an 
Aeris 3.6 µm Widepore XB-C18 LC 100 x 2.1 mm Column (Phenomenex, CA, USA), as previously 
described [37]. Briefly, mobile phases A and B consisted of 0.1 % trifluoroacetic acid (v/v) in either 
ultrapure water or acetonitrile HPLC grade, respectively. Column temperature was set at 30 ℃, and 
the run from 10% to 100% of phase B in 5 min, and 3 min to 10%. A calibration curve generated with 
known concentrations of the peptide, both in water and in the disassembled NPs (6.5 – 100 mg/L, R2 = 
0.99) was used to quantify the amount of PCS5 in each sample. 
At CIDETEC, the quantification of the peptide was carried out using a High Performance Liquid 
Chromatography (HPLC), in an Agilent model 1100 series LC with UV detector, the ChemStation 
software (Agilent Technologies, CA, USA) and with a X Bridge BEH C18 2.5 μm 4.6 x 100 mm column 
(Waters Corporation, MA, USA). Mobile phases A and B consisted of 0.1 % trifluoroacetic acid (v/v) in 
either ultrapure water or acetonitrile HPLC grade, respectively. Column temperature was set at 30 ℃, 
and the run from 10% to 100% of phase B in 12 min at flow rate of 0.65 mL/min. A calibration curve 
generated with known concentrations of the peptide, in water and in the disassembled NPs (6.5 – 100 
mg/L, R2 = 0.99) was used to quantify the amount of PCS5 in each sample.  
At UT2A, samples were analyzed with an Agilent 1260 series autosampler and a HPLC pump (Agilent 
Technologies, CA, USA) equipped with a Superdex peptide 10/300GL column (GE Healthcare, IL, USA) 
and an UV-Visible detector operating at 214 nm (VWD 1200 series, Agilent Technologies, CA, USA), as 
already reported [43]. In this case, peptide elution was done with 50 mM phosphate buffer and 150 
mM sodium chloride, with flow rate of 0.7 mL/min for 35 min. Calibration was obtained with peptide 







A NanoAssemblr microfluidics device (Precision nanosystems, Vancouver, Canada) was used for the 
preparation of the NPs. The cartridges used were 200 μm wide and 79 μm high, while the mixing area 
had a herringbone structure that was 31 μm high and 50 μm thick. To assess the influence of the total 
flow rate, flows ranging from 0.5 mL/min to 14 mL/min were used, with initial polymer concentrations 
of 0.63 mg/mL of CS and 1.875 mg/mL of DS and a 1:1 flow ratio. For the loaded NPs, the CS solution 
had a PCS5 concentration of 0.27 mg/mL. NPs were characterized by DLS.  
 
2.8.2. Batch-mode 
For the preparation of 200 mL batches, a propeller stirrer IKA RW 20 (Staufen, Germany; 4-blade, stir 
diameter 50 mm, shaft diameter 8 mm, and shaft length 350 mm) was used to mix the different 
solutions. To 93.3 mL of an aqueous solution of CS (0.67 mg/mL), 6.7 mL of either ultrapure water or 
an aqueous solution of PCS5 (4 mg/mL) were added under stirring at 700 rpm, and let to mix for 5 min. 
Then, 100 mL of an aqueous solution of DS (1.875 mg/mL) were poured onto the CS/PCS5 solution, 
kept under stirring for 5 min and standing for 10 min. Supplementary Video S1 shows the formulation 
procedure of the loaded NPs. 
 
2.9.  Statistical analysis 
Data analysis was performed with GraphPad Prism version 7.0 (GraphPad Inc). Statistical comparison 
was done using ANOVA, followed by a Dunnett’s multiple comparison test. Data are expressed as the 
mean ± standard deviation (SD). p values of 0.05 or less were considered statistically significant. 
 
3. Results and Discussion 
The complexity of some nanoformulations and the lack of well-defined standard analytical 
methodologies for their complete characterization are some of the hurdles that have hampered the 
arrival of nanomedicines to the market [17]. In fact, these difficulties for the translation of NPs 
preparation technique from a lab to an industrial scale were recently described in a report by Couvreur 
el al. [19]. Therefore, it has become clear that the assessment of reproducibility and the selection of 
adequate characterization methods are critical steps to be considered in the scientific literature. Here, 
our aim was to transfer the development of a potential nanovaccine candidate from the bench to an 
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industrial environment, highlighting the critical requirements that all nanovaccine candidates should 
fulfill in order to progress towards commercialization. 
 
3.1. Implementation of a quality-by-design approach 
The aim of a QbD approach is to understand how the formulation and processing parameters affect 
the properties of the formulation. This knowledge is critical in order to generate more robust and 
reproducible nanomedicines [44]. Here, the quality target product profile (QTPP) of the 
nanoformulation was first established (Table 1), following ICH recommendations [40]. The QTPP was 
determined by the indication and the modality of administration. In this sense, based on the positive 
data obtained in macaques [36,38], the product was defined for vaccination against HIV and for 
intranasal administration (Table 1). In order to maintain the long-term stability, the product was 
formulated as a freeze-dried powder that could be rapidly dispersed in water at the moment of 
administration (Table 1).  
Table 1 Quality Target Product Profile (QTPP) of the HIV vaccine candidate 
Parameter Target Justification 
Indication HIV vaccine PCS5 has been reported to be one potential antigen in HIV [45] 
Route of 
administration 
Nasal Good preliminary results through this route, improves patient 
compliance [36] 
Dosage form Freeze-dried powder To increase long-term stability 
API content 100 µg/mL Required antigen dose for macaque studies 
Packaging Type I glass vials Recommended by USP and Eur. Ph. for injectable formulations 
and able to resist thermal shocks (for freeze-drying) 
Stability At least 1 year at room 
temperature 
To guarantee an acceptable stability  
Dispersibility In 10 s, by manual 
shaking 
To facilitate self-preparation and administration – no need of 
training or specialized equipment 
Moisture < 3% To avoid API degradation or bacterial growth 
 
As a second step, the critical quality attributes (CQAs) were defined (Table 2). CQAs are the main 
physical, chemical and biological attributes, which are critical to guarantee the safety and efficacy of 
the nanoformulation (Table 2) [39]. These details were gathered from the knowledge our research 
group has from working on the development of this type of nanocarriers, from the specific 
recommendations from the FDA and the EMA, and also from the different Pharmacopeias. More 
precisely, both the composition of the CS/DS NPs and the antigen dose selected were already tested 
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in vivo, with promising results [36,38]. Indeed, CS and DS are two polysaccharides used in nanovaccines 
due to their biocompatibility, biodegradability, and low toxicity, and that have also shown to improve 
the immune response against many antigens [35,46–49]. Furthermore, CS has an FDA GRAS status. 
The values of the physicochemical properties of the NPs were based on the literature, where 
nanometric sizes have been shown to perform better than micrometric sizes for the delivery of 
biomolecules through the nasal route [50]. Within the nanometric range, medium size NPs (200 nm) 
elicited stronger responses than very small sizes (30 nm) [51]. In terms of the surface charge, it is 
important to find a balance between mucoadhesion and mucodiffusion [11]. Finally, values as 
osmolality, pH, moisture and microbiology have been selected from the literature and FDA 
recommendations [52–54].  
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Table 2 Critical quality attributes (CQAs) of the formulation 
CQAs Target Justification 
Components Dextran sulfate, sodium salt 
Chitosan, hydrochloride salt 
Peptide antigen (PCS5) 
Highly purified water (type I) 
Materials of the original formulation; water for 
parenteral administration [36,38] 
Content uniformity 82.25 mg ± 10% Amount needed for an adequate dosing of API 
API content 100 µg/mL Dose used in macaques [36,38] 
Particle size and 
distribution  
100–300 nm 
D(10) 80–150 nm 
D(50) 150–250 nm 
D(90) 250–450 nm 
Span 0.4–3 
Adequate size for nasal administration and for the 
interaction with immune cells [11] 
Polydispersity < 0.3 Physicochemical properties that guarantee 
reproducibility 
Surface charge -30 to -65 mV Adequate values to prevent aggregation in the 
mucus, and to ensure a longer stability [11] 
Osmolality 100–200 mOsm/Kg Adequate for nasal administration 
pH 5–7.5 Adequate for nasal administration [52] 
Dispersibility  10 s For an easy extemporaneous formulation preparation 
Microbiology TAMC: 102 CFU/g  
TYMC: 101 CFU/g  
E. coli: Absence/mL 
Adequate for nasal administration [53] 
Water content ≤3% To avoid API degradation and bacterial growth [54] 
TAMC, Total Aerobic Microbial Count; TYMC, Total Combined Yeast and Mold Count. 
 
Once the CQAs of the product were selected, the subsequent step was a risk analysis of the impact of 
different parameters in the CQAs of the formulation [40]. In general, these parameters are related to 
the characteristics of the starting materials (i.e., polymers, drug, solvents or ratios), the different steps 
in the manufacturing process (i.e., phase incorporation rates, incubation times or agitation speeds) 
and also the environmental factors. In this case, an Ishikawa diagram was sketched to illustrate which 
specific parameters could alter the CQAs of our nanoformulation (Fig. 1). This risk management tool 
allowed to identify the potential variables that could have a harmful effect on the formulation 
attributes. Overall, the factors related to the preparation process had to be further monitored and 
controlled (Fig. 1), and their influence was rigorously analyzed as described in the following section.  
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Fig. 1 Ishikawa diagram of the composition and manufacturing factors that influence the quality attributes of the 
nanoformulation. Interaction time refers to the time that the components are interacting under stirring; while 
incubation time refers to the same condition, but in the absence of agitation (more details in Figure 2) 
 
3.2.  Nanoparticles fabrication. Determination of the critical process parameters  
NPs were prepared by ionic complexation of the positively charged components (CS and the peptide 
PCS5) and the negatively charged DS, to a final concentration of 0.31 mg/ml of CS, 0.13 mg/mL of PCS5 
and 0.94 mg/mL of DS. The fabrication process of the NPs is represented in Figure 2a. Accordingly, and 
following the Ishikawa diagram (Fig. 1), we studied how the different formulation steps influenced the 
final NP properties. Namely, we analyzed how the incorporation rate of DS solution over the CS/PCS5 
solution affected the characteristics of the NPs. For this purpose, the DS solution was added dropwise 
(which would represent a low incorporation rate), with a pipette (medium incorporation rate, as in the 
original protocol) or using a syringe (to achieve high phase incorporation rates). As shown in Figure 
2b,c, the dropwise incorporation (represented as “low”) caused the aggregation of the NPs, with 
significant changes in particle size and PDI. However, the other two procedures led to particles of 
adequate physicochemical properties (particle size close to 150 nm, PDI lower than 0.2 and negative 
surface charges). Other parameters such as the agitation speed of the CS/PCS5 phase while adding DS, 
the time of interaction with DS, or the incubation time were also evaluated (Fig. 2). All procedures 






















































Overall, the most critical parameter to monitor when translating this manufacturing process will be 
the incorporation rate of DS over the CS/PCS5 phase, because a low incorporation rate will cause the 
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Fig. 2 Nanoparticle manufacturing process and effect of the different steps on the physicochemical properties of 
the formulation. (a) Fabrication of the nanoparticles. The peptide antigen is added to the chitosan solution. Then, 
(1; phase incorporation rate) the solution of dextran sulfate is incorporated into the chitosan/peptide solution, 
(2; agitation speed) under magnetic stirring. (3; interaction time) Components are kept under agitation to allow 
their interaction, and then (4; incubation time) they are kept for 10 additional min in the absence of agitation. 
(B,C) Effect of the manufacturing parameters on the physicochemical properties of the nanoparticles. (b) Particle 
size and PDI, and (c) Zeta-potential values were monitored for the different processes: phase incorporation rate, 
agitation speed, interaction time and incubation time. Hyphens represent the values that are constant, as in the 
first column. Values represent mean ± SD (n ≥ 3). A statistical comparison was done using a one-way ANOVA, 
followed by a Dunnett’s multiple comparison test. Significant statistical differences are represented as **** (p < 
0.0001) in comparison to the original protocol 
 
3.3. Characterization of particle size and size distribution 
The selection of adequate analytical methods for the characterization of nanostructures is a key step 
in the development of a nanomedicine [16,55]. Dynamic light scattering (DLS) techniques are fast and 
easy methods to determine particle size and polydispersity [56]. For the particles here studied these 
values were about 120 nm for size, PDI of 0.2 and negative surface charge (Fig. 3a,d). Nevertheless, 
this method has several drawbacks, such as a bias towards detecting the larger particles of the sample, 
limited resolution between subpopulations with similar particle size, or the assumption that the 
particles are spherical [56]. To overcome these biases, the combination with other complementary 
orthogonal techniques is highly recommended by specialized organizations such as the European 
Nanomedicine Characterization Laboratory (EUNCL) or the US National Cancer Institute 
Nanotechnology Characterization Laboratory (NCI-NCL), that works jointly with the FDA [57]. Electron 
microscopy imaging can help identify the shape and geometry of the NPs, as well as confirm their 
distribution and size in number [57]. Indeed, transmission electron microscopy studies corroborated 
that the developed NPs were spheres, with sizes in the 100–200 nm range (Fig. 3b,d). NTA analysis, 
although also based on light scattering, is able to track individual particles, allowing to better 
distinguish between subpopulations of particles with similar particle size [56]. Here, NTA was used as 




Fig. 3 Physicochemical characterization of the nanoformulation. (a) DLS intensity histograms (top) and surface 
charge values (bottom), (b) Micrographs of the NPs by FESEM with the STEM detector (size bar represents 200 
nm), and (c) NTA size distribution. (d) Summary of the mean size values of the nanoparticles measured by the 
three complementary techniques evaluated 
 
3.4. Content uniformity monitorization 
The selection of the adequate methods for the quantification of both the number of NPs and the 
quantity of drug associated to them is an essential step to guarantee the uniformity of the formulations 
and their batch-to-batch reproducibility. 
3.4.1. Methods for particle content evaluation 
Derived count rate is a parameter given by DLS measurement that represents the scattering intensity 
measured in the absence of a laser light attenuation filter, making it a convenient parameter to obtain 
the particle concentration [58,59]. Although it is not a direct measure of the number of particles within 
the formulation, it can be used as an indirect measurement for the purpose of comparison between 
batches, and its use is recommended by the EUNCL at the prescreening phases [58]. It is important to 
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different particles concentrations tested [59]. In this case, different dilutions of the initial 
nanoformulation showed a linear correlation (R2 > 0.998) with the values of the derived count rate 
(Supplementary Material, Fig. S1a). Nevertheless, since the lasers of different devices are not 
identically calibrated, the overall values are not comparable among them (data not shown). Therefore, 
DLS was a suitable measurement of the content uniformity as an internal control. 
The determination of the turbidimetry (values of transmittance) has classically been a way to have a 
gross estimation of the concentration of particles in suspension, with the premise that particle size 
also has to remain constant [59]. Using ultrapure water as a blank (100% transmittance), a linear 
correlation (R2 > 0.942) between the percentage of transmittance and the concentration of the 
formulation was reported (Supplementary Material, Fig. S1b). Furthermore, the fact that the 
transmittance values were similar between different laboratories, confirms them as an interlaboratory 
validation method for the manufacturing process of the nanoformulation. 
 
3.4.2. Evaluation of the API content 
The determination of the drug content is a parameter that deserves special attention. In this case, an 
UPLC method to analyze the peptide antigen (PCS5) has already been described [37]. For PCS5 
quantification, NPs were, first, disassembled in order to release the peptide. Since NPs were mainly 
formed through ionic interactions between the two polymers and the peptide (isoelectric points values 
of: pICS, 6.5; pIDS, < 2; pIPCS5, 11), the use of a hypertonic medium was expected to disrupt the particles 
and allow the quantification of the peptide. Indeed, high concentrations of KCl (2 M) led to the 
disassociation of the particles, verified by a 100% recovery of the peptide. This was also confirmed by 
a dramatic decrease in the derived count rate values (Supplementary Material, Fig. S2a). 
Additionally, calibration curves of the peptide in water and in the matrix (blank NPs disrupted with 2M 
KCl) showed no influence of the matrix for the quantification of PCS5, confirming the specificity of the 
method. Additionally, linear calibration curves with R2 > 0.999 were obtained in both cases 
(Supplementary Material, Fig. S2b). The accuracy and precision of the method were also confirmed 
(data not shown). 
 
3.5. Aseptic manufacturing 
According to FDA regulations, nasal sprays do not need to be sterile for patient administration, 
nevertheless, the microbial content has to be controlled [53]. To do so, from the different sterilization 
methods available, we selected filtration as the one to guarantee a low microbial burden [60]. At the 
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same time, it is important to bear in mind that having reliable and reproducible methods to reduce the 
microbial burden is crucial to guarantee the safety of the product. In fact, problems related to the 
sterilization of Doxil®/Caelyx® were reported in 2011, and caused an important drug shortage [22,61].  
The effect of the filter material (PVDF, PES or PTFE) over some CQAs (e.g., particle size and number of 
particles) was studied in order to select the most adequate filter. It has been described that for an 
effective filtration through a 0.22 µm mesh size filter, particle size should be smaller than 200 nm, 
preferably bellow 100 nm [62–64]. The assessment of the value of the filtration process was assayed 
for the nanoformulation and, although the results showed no significant changes in the particle size 
when using the different filters (Fig. 4a), a 15–30% decrease in the derived count rate was observed 
after filtration (Fig. 4b), indicating that a certain number of NPs did not pass through the filters. 
 
Fig. 4 Effect of NP filtration through different 0.22 µm filters in terms of (a) particle size and (b) derived count 
rate after filtration, in comparison to the non-filtered particles (na). Values represent mean ± SD (n = 3) 
An alternative procedure to decrease the potential impurities of the NPs would be the filtration of the 
starting materials. To determine the feasibility of this approach, solutions of CS and DS were filtered 
through 0.22 µm PVDF filters, and then freeze-dried to determine the yield of the process. The 
recovery yields obtained were 94 ± 5% for CS, and 100 ± 7% for DS. Furthermore, the NPs formulated 
with the filtered materials presented the same attributes as the ones with non-filtered components 
(Supplementary Material, Table S1). Therefore, starting materials could also be filtered to minimize 
the microbial burden of the final formulation, without modifying any other attributes. 
 
3.6. Long-term stability of the freeze-dried formulation 
A long-term stability at room temperature is a highly desirable attribute for any vaccine. Having this 
feature would eliminate the need for the cold chain and would facilitate the accessibility of the vaccine 

















































stability under storage for long periods of time. Trehalose was selected as a cryoprotectant, since its 
use has been proven to maintain the physicochemical properties of the NPs [37].  
The characterization of the NPs by DLS, microscopy, and NTA confirmed that the particle size values of 
the nanoformulations were barely altered during the freeze-drying process (Supplementary Material, 
Fig. S3). In fact, a modest increase in particle size by the three techniques was observed. An analysis 
of the content uniformity yielded transmittance values of 4 ± 2%; and a peptide recovery of 96 ± 13%, 
confirming the stability after the lyophilization process. The resuspended freeze-dried formulation also 
presented a pH of 6.5, appropriate for nasal administration [52]. Regarding the osmolality, values of 
approximately 149 mOsm/Kg were obtained. Finally, the residual moisture after freeze-drying was also 
tested, providing values lower than 3%, which have been reported to be adequate to avoid unwanted 
bacterial growth [54]. 
In agreement with the ICH guidelines, the evaluation of the long-term stability of the freeze-dried NPs 
[65], was performed at 5 ℃	for simulating the storage in a refrigerator, 25 ℃/60% relative humidity 
(RH) for a general long-term stability study, and at 40 ℃/75% RH for an accelerated stability study. 
Some physicochemical properties (particle size, PDI and Z-potential), API content and pH were 
monitored over time. All these attributes were found within our specification values for up to 15 
months in storage, both for the refrigerator and the general long-term stability conditions (Fig. 5). Only 
in the case of the accelerated study (40 ℃/75% RH), the pH value was below the specification range 
(Fig. 5d), which could be related to the degradation of the components [66]. 
These results evidence the necessity of establishing and tracking all key attributes to guarantee a good 
characterization and understanding of the developed nanoformulations. They also underline that the 
nanovaccine here developed is stable for over a year without the need of the cold chain. 
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Fig. 5 Long-term stability of the freeze-dried NPs at 5 ℃; at 25 ℃/60% RH; and at 40 ℃/75% RH. Evolution of (a) 
particle size and PDI, (b) zeta-potential, (c) % of peptide recovery and (d) pH. The red box highlights the values 
that are not within the CQAs. Values represent mean ± SD (n ≥ 3) 
3.7. Technology transfer 
Another important requirement for the good manufacturing of a nanoformulation is to ensure that 
the production procedure is reproducible with different batches of the forming polymers, as well as 
across different people and laboratories. First, we compared the physicochemical properties of the 
NPs prepared with three different batches of CS, and two different batches of DS, confirming the 
reproducibility of the formulation (Supplementary Material, Table S2). Additionally, the formulation 
process was transferred to three different laboratories (at the University of Santiago de Compostela, 
at the CIDETEC Nanomedicine, and at UT2A laboratory), with different personnel, and the resulting 
batches of loaded NPs (from 1.65 to 200 mL) were thoroughly characterized and compared. In all three 
centers, the physicochemical properties of the different batches were found to be within the 
specification values previously established in the CQAs (Supplementary Material, Table S3). These 
results further highlight the suitability of these polymeric NPs for a successful translation from bench 
to an industrial level. 
 
3.8. Scaling up by a microfluidic-based and a batch-mode method 
Bearing in mind that the ultimate goal of this nanoformulation development was an industrial 
translation, a scale-up from the original batch size (1.65 mL) to a more suitable size for preclinical and 
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clinical studies was a fundamental step in this work. Thus, we studied both a continuous and 
discontinuous scale-up procedure, by the adaptation of microfluidics for the production of the NPs and 
the preparation of a 200 mL batch. Finally, a 200-mL batch was produced in the pilot plant under GMP-
like conditions. 
 
3.8.1. Continuous production of the nanoparticles using microfluidics  
Microfluidics has emerged as a potential tool to produce highly reproducible nanoformulations, with 
the additional advantage of scalability [67]. In this case, a staggered herringbone mixer was employed 
for the preparation of the NPs [68]. Most nanosystems prepared by this technique are based on the 
nanoprecipitation of the materials when the organic and aqueous phase meet, while in our case the 
particle formation relied on the ionic interactions between two oppositely charged phases. The 
satisfactory application of this technique for a solvent-free NP formation has been recently disclosed 
for the preparation of octa-arginine/RNA nanocomplexes [69]. Considering that the process 
parameters may have an important effect in the properties of the resulting NPs [70], here, we first 
conducted a screening of the influence of the flow rates over the production of blank NPs. Then, the 
method that provided the best result was applied to the loaded NPs. The cartridge employed consisted 
on two inlets, one for the positively charged phase and the other for the negative DS phase, followed 
by a mixing area and finally an outlet to collect the formed NPs (Fig. 6a). Solutions of CS and DS were 
prepared at the same concentrations as the ones used for smaller batches; the flow ratio was kept 
constant at 1:1, and the flow rate was the parameter of study (from 0.5 to 14 mL/min).  
For the blank NPs, the particle size decreased as the flow rate values were increased, but at the same 
time, higher variability was detected (Fig. 6b). Interestingly, the higher flow rates also yielded smaller 
derived count rate values (Fig. 6c). On the other hand, the lowest flow rate tested (0.5 mL/min) 
generated reproducible particles, with properties closer to our nanoformulation CQAs (Fig. 6b,c). In 
this regard, we have hypothesized that the high flow rates (of 3 mL/min or more) might hinder the 
adequate interaction time between the oppositely charged polymers. This incomplete interaction 
would lead to a higher amount of free components, resulting in low derived count rate values. When 
testing these conditions for the loaded NPs, similar physicochemical properties to the ones produced 
by a discontinuous method were obtained (Fig. 6d). Therefore, the nanoformulation of study could be 
produced with microfluidics, which allows to envisage a continuous and scaled-up production.  
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Fig. 6 Scale up using microfluidics. (a) Design of the cartridge used. Influence of the different flow rates in (b) 
particle size and PDI, and in (c) Z-potential and derived count rate. (d) Physicochemical properties of the loaded 
NPs prepared with a flow rate of 0.5 mL/min. Values represent mean ± SD (n = 3). NPs, nanoparticles; PDI, 
polydispersity index 
 
3.8.2. Batch mode production of the nanoformulation 
The NPs were prepared by ionic complexation, a method that has been described as easily scalable 
[71]. In the particular case of the NPs here studied, the magnetic stirring of the small batches was 
substituted by a mechanical stirring with a blade agitator, more suitable for an accurate control when 
large volume solutions are mixed. As studied in section 3.2., the most critical parameter to obtain 
adequate NPs and prevent aggregation was the incorporation rate of the DS solution over the CS/PCS5 
phase. Thus, for this scale-up, the mechanical stirring was kept at 700 rpm, and the DS solution was 
poured manually (Supplementary Material, Video S1).  
First, 200 mL batches of blank NPs were prepared to confirm the suitability of the procedure for a 
larger scale, and then the same procedure was applied to prepare the loaded NPs. Particle size, PDI, Z-
potential and pH were monitored to evaluate the method performance. As shown in Table 3, all values 
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were found within the product specifications previously described. Therefore, this discontinuous 
method was proven to be suitable for the production of large volumes of NPs, with no important 
effects over any of their physicochemical properties. 
Table 3 Physicochemical properties of the scaled-up blank and loaded nanoparticles in comparison with the 
small-size batches 
Sample Particle size (nm) PDI ζ-potential (mV) pH Transmittance (%) 
Blank NPs 
(1.65 mL batch) 
95 ± 8 0.16 -41 ± 4 7 ± 0.2 25 ± 4 
Blank NPs 
(200 mL batch) 
99 ± 8 0.14 -39 ± 1 7 ± 0.4 24 ± 5 
Loaded NPs 
(1.65 mL batch) 
130 ± 15 0.14 -45 ± 7 6 ± 0.6 6 ± 3 
Loaded NPs 
(200 mL batch) 
129 ± 4 0.15 -41 ± 6 6 ± 0.2 3 ± 2 
FD NPs 
(1.65 mL batch) 
160 ± 15 0.16 -43 ± 7 7 ± 0.6 4 ± 2 
FD NPs 
(200 mL batch) 
182 ± 11 0.19 -45 ± 3 6 ± 0.7 3 ± 2 
Values represent mean ± SD (n ≥ 3; except for loaded and FD NPs 200 ml batch, where n = 2) 
FD, freeze-dried; PDI, polydispersity index; NPs, nanoparticles 
 
We have seen in this section that the formulation of CS/DS NPs can be translated to an industrial 
environment and fabricated either by discontinuous (batch-mode) or continuous (microfluidics) 
methods. In the case of the batch-mode preparation, it is a simple and fast method, that may need 
subsequent adaptations with the increase in the batch size. On the other hand, microfluidics is a very 
reproducible technique that can produce high NP volumes by using several cartridges in a row. 
Nevertheless, these cartridges are costly, and have a limited lifetime and re-usability, thus increasing 
the final cost of fabrication. These aspects have to be taken into consideration when selecting the 
methods for an industrial translation. 
 
3.8.3. Production of a GMP-like batch in the pilot plant 
As the last step on the road to the translation of the nanomedicine, a 200 mL batch volume was 
selected to be prepared in the pilot plant. This batch size, equivalent to 220 doses of the vaccine 
candidate, was considered to be sufficient for an exploratory preclinical study with 50 non-human 
primates and four boosts per animal. Furthermore, all the procedures in the pilot plant were 
conducted under GMP-like conditions. In this regard, production processes, materials and personal 
flow were designed in qualified facilities according to GMP guidelines. All the components used to 
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prepare the formulation were qualified as GMP grade materials, with the exception of the peptide 
antigen. To prepare the GMP-like batch, the starting polymer solutions (CS and DS) were first filtered 
through 0.2 µm mesh size filters, as described in section 3.5. Then, the formulation was prepared under 
mechanical stirring with a blade agitator. Subsequently, formulation and cryoprotectant were added 
to type I glass vials, to then be freeze-dried. The resulting formulation was redispersed in highly 
purified water and characterized. The physicochemical properties of the NPs were found within the 
CQAs previously described (Table 4). Therefore, the translation of the nanovaccine from the bench to 
an industrial environment has been successfully achieved. 












Final formulation 150 ± 1 0.13 -42 ± 1 6.6 7.2 186 
FD, freeze-drying; PDI, polydispersity index; NPs, nanoparticles; transm, transmittance 
Overall, we consider that this work compiles in a great manner with the MIRIBEL recommendations 
for material characterization [31]. Here, we have provided a detailed description of the synthesis 
method of the formulation, together with an evaluation of the different parameters that may have an 
effect on the final NPs. Furthermore, the values of size, shape, zeta potential, density, concentration 
and drug loading were thoroughly studied and reported in this work, and in many cases confirmed by 
several complementary techniques. Besides, three different batches of the forming components have 
been employed to guarantee the reproducibility of the formulation, among other aspects. Overall, the 
results of this manuscript compile with the MIRIBEL recommendations, which we hope will help in the 
standardization and application of stablished methodologies for the characterization of nanosystems. 
 
4. Conclusions 
In this work, we demonstrated the feasibility to manufacture an potential HIV nanovaccine candidate 
in a pilot plant. By implementing a QbD approach, the most critical aspects of the process that have an 
impact on the formulation attributes were highlighted. This strategy helped to identify that the phase 
incorporation rate had the most significant effect over the final properties of the nanoformulation. In 
addition, we emphasized the importance of combining orthogonal techniques to guarantee a realistic 
and complete characterization of the formulation. The definition of all these critical process 
parameters led to the successful transfer of the HIV nanovaccine manufacturing procedure from the 
laboratory to the pilot plant production, and its scale-up by both the microfluidic and the batch mode 
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methods. All these results validate that the nanomedicine would be ready to move towards an 
industrial manufacturing set up. 
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Supplementary Fig. S1 Calibration curves for the determination of nanoparticle content using (a) the values of 






Supplementary Fig. S2 Nanoparticle disassembling in the presence of high ionic strength solutions. (a) Effect of 
the concentration of KCl on the derived count rate. (b) Calibration curves of the peptide PCS5 in water (red) and 
in NPs disrupted with KCl (matrix, in dark blue). Values represent mean ± SD (n = 3) 
a b
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Supplementary Fig. S3 Physicochemical characterization of the redispersed freeze-dried nanoparticles. (a) DLS 
intensity histograms (top) and surface charge vaules (bottom), (b) Micrographs of the NPs by FESEM with the 
STEM detector (size bar represents 200 nm), and (c) NTA size distribution. (d) Summary of the mean size values 




Method Size ± SD (nm)
DLS 160 ± 15
TEM 187 ± 57
NTA 144 ± 12
Size (nm)
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Supplementary Table S1 Comparison of the physicochemical properties of the nanoparticles prepared with non-
filtered and filtered starting materials 
Starting materials Particle size (nm) PDI Ζ-potential (mV) Derived count rate (kcps) 
Non-filtered 138 ± 14 0.14 -53 ± 4 65300 ± 1900 
Filtered 135 ± 12 0.15 -50 ± 3 51500 ± 1600 
PDI, polydispersity index 
 
 
Supplementary Table S2 Comparison of the physicochemical properties of the nanoparticles prepared with 
different batches of chitosan and dextran sulfate  
CS batch DS batch Particle size (nm) PDI Ζ-potential (mV) 
batch 1 batch 1 118 ± 7 0.15 -45 ± 5 
batch 2 batch 1 135 ± 4 0.14 -41 ± 1 
batch 2 batch 2 113 ± 9 0.12 -46 ± 2 
batch 3 batch 2 128 ± 4 0.14 -46 ± 2 
CS, chitosan; DS, dextran sulfate; PDI, polydispersity index 
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Supplementary Table S3 Comparison of the physicochemical properties of the resuspended nanoparticles prepared in three different laboratories with the established 
specifications (CQAs) 

















<0.3 -30– -65 82.245 ± 10% 5 –7.5 100–200 < 10% Yes < 5% 90–110% 
USC 164 ± 24 
D(10) 99 ± 10 
D(50) 171 ± 17 
D(90) 308 ± 44 
Span 1.2 ± 0.2 
0.16 -43 ± 7 75.6 ± 0.5% 7 ± 0.6  149 ± 4 4 ± 2% Yes n.d. 96 ± 13% 
UT2A 
[1] 
181 ± 6 
D(10) 139 ± 6 
D(50) 229 ± 12 
D(90) 377 ± 34 
Span 1.1 ± 0.1 
0.17 n.d. n.d. n.d. n.d. n.d. Yes n.d. 110 ± 2% 
CIDETEC 157 ± 17 
D(10) 96 ± 11 
D(50) 170 ± 8 
D(90) 309 ± 4 
Span 1.3 ± 0.2 
0.17 -45 ± 7 n.d. 6 ± 1 154 ± 6 5 ± 2% Yes 1 ± 0.4 100 ± 4% 
n.d., not determined; PDI, polydispersity index; Transm, transmittance 
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